Astellas Partnership Opportunities 2026-2028: Where You Fit

The next three years will be a proving period for Astellas. Its new Corporate Strategic Plan 2026, CSP2026, is built around a clear transition. Astellas wants to maximise revenue from today’s strategic brands while accelerating the pipeline assets expected to drive growth from FY2029. For your company, that creates real opportunities. But a general claim that you can support innovation will not be enough. It’s your responsibility to show where exactly you fit, what risks you remove, what processes you improve and how you can help Astellas move faster.

What is Astellas?

Astellas Pharma is a Japanese-headquartered global life sciences company, created in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. It now has more than 13,500 employees worldwide.

In FY2025, Astellas reported sales revenue of approximately JPY 2.1 trillion and R&D expenditure of JPY 291.8 billion. Its current commercial strengths include oncology, ophthalmology, urology, immunology and women’s health. Its five strategic brands are PADCEV, IZERVAY, VYLOY, VEOZAH and XOSPATA.

This is not simply a large Japanese pharmaceutical company looking for more products. Astellas is trying to become a more focused, pipeline-led growth company with global reach and a stronger ability to turn specialised science into commercial assets.

Astellas then and now: what changed

A few years ago, CSP2021 presented Astellas as a company building a broad set of technology platforms and trying to convert them into clinical proof. It highlighted 31 Primary Focus projects aiming for proof of concept by the end of FY2025, multiple cell and gene therapy platforms, and greater in-house self-sufficiency in AAV and cell therapy manufacturing. Commercially, the plan still leaned heavily on XTANDI plus a group of strategic products.

That Astellas was receptive to platform stories because it was still building the machinery. External companies could be interesting because they added a modality, target, tool or capability to a portfolio intended to generate many proof-of-concept candidates.

The Astellas described in CSP2026 is not abandoning that scientific model. The Primary Focus logic remains. But the centre of gravity has moved. The company is now managing a controlled transition from established and strategic brands to pipeline-led growth from FY2029. It wants at least 10 Phase 3 or pivotal starts during CSP2026, including at least five by FY2027, and it is putting stronger governance around portfolio choices.

This makes today’s Astellas more selective, more asset-specific and more execution-hungry. It is strengthening critical in-house capabilities, internalising selected clinical operations and using value-enhancing business development rather than rescue BD as the default. External innovation remains important, but it now has to fit an end-to-end operating model.

Put simply, the old question was often: Can this technology create an interesting programme? The new question is more likely: Can this asset or capability improve a named decision, accelerate a pivotal programme, strengthen a strategic brand or remove a scale-up risk?

This is good news for the right partner. It is bad news for broad platform decks, generic service catalogues and conversations that begin with: perhaps Astellas can find a use for this.

Where is Astellas going strategically?

CSP2026 covers FY2026 through FY2030. The ambition is pipeline-led, record-high revenue by the mid-2030s. The critical transition begins now.

Astellas has committed to:

• Start more than 10 Phase 3 or pivotal studies during CSP2026, including at least five by FY2027.
• Drive growth from FY2029 through pipeline assets.
• Double sales from its five strategic brands by FY2030 compared with FY2025.
• Maintain average base R&D investment at about 20% of revenue, with additional investment of up to 5%.
• Use external collaboration, data and AI to improve R&D productivity.
• Pursue disciplined, value-enhancing business development.
• Increase speed and consistency in clinical-trial execution.

The important words are speed, focus and value. Astellas is not signalling indiscriminate spending. It is making larger commitments around selected assets, modalities and capabilities.

Which therapeutic areas and modalities matter?

Astellas combines disease biology, modality or technology and diseases with high unmet need. Its four Primary Focuses provide the clearest map.

The CSP2026 pipeline also includes mRNA, cell therapy, gene therapy, T-cell engagers, conventional and immunostimulatory ADCs, targeted protein degraders and small molecules. The current pipeline page additionally lists antibodies, oncolytic viruses and pegylated RNA aptamers. This does not mean Astellas is equally interested in every modality. Strategic fit still matters more than novelty alone.

What is Astellas looking for?

The answer depends on what your company brings.

1. Assets and platforms that strengthen the chosen pipeline

Astellas says that external partnerships have contributed to more than half of its pipeline and products. The company uses academic alliances, research collaborations, licensing, global pharmaceutical partnerships and acquisitions.

The strongest fit is likely to be an asset or platform that supports one of the four Primary Focuses, adds differentiated biology or improves a modality in which Astellas already has capabilities.

In practical terms, this could include:

• A moderately de-risked clinical asset in a defined therapeutic area.
• A platform that improves target selection, payload design, delivery or patient selection.
• Next-generation AAV vectors, safer serotypes or more efficient tissue targeting.
• Cell therapy assets compatible with Universal Cell technology.
• Less invasive ocular delivery.
• Technologies that improve cell and gene therapy CMC, scalability or consistency.
• New immune-engaging or induced proximity approaches with a clear biological rationale.

2. Business development that adds value, not volume

Astellas is explicit about its business-development priorities. It plans to pursue value-enhancing BD as its core approach. This includes synergistic pipeline assets, moderately de-risked programs in predefined therapeutic areas or modalities and, selectively, near-launch or marketed assets.

Large-scale company or asset acquisitions remain possible, particularly where they protect near-term revenue. But CSP2026 says that rescue BD is not the default. The opportunity is therefore strongest when your asset complements capabilities Astellas already possesses and creates a credible route to value.

This is relevant for in-licensing, co-development, regional or global commercial rights and M&A discussions.

There is also an opportunity in the opposite direction. Astellas maintains a public route for companies interested in acquiring selected Astellas R&D programs. As of September 2026, the listed divestiture programs include ASP3819 and ASP2616. For a company seeking differentiated IP to develop, this deserves attention.

3. Open innovation with a defined scientific purpose

Astellas’ open-innovation model includes SakuLab-Tsukuba, TME iLab in Kashiwa-no-ha and SakuLab-Cambridge. These are not merely networking spaces. They are designed to connect external science with Astellas’ internal drug-discovery capabilities.

For your company, the opportunity may be a research collaboration, platform validation, shared laboratory work, access to specialised capabilities or a relationship that could mature into licensing or investment.

The best entry point is a specific scientific question. A broad corporate presentation will rarely create momentum.

What real opportunities look like

An opportunity is not a category such as oncology, gene therapy, AI or clinical services. It is a specific problem, owned by a specific Astellas team, at a point where an external capability can change the outcome.

In-licensing, co-development and M&A

A real asset opportunity has a clear connection to an Astellas Primary Focus, strategic brand or named pipeline need. It may be a moderately de-risked clinical asset, a differentiated programme in a predefined modality, or a platform with enough validation to generate more than one credible candidate. Astellas should be able to see the development logic, the commercial rights available and the work needed to reach the next value inflection.

A real M&A opportunity can also protect near-term revenue or add a capability that Astellas would struggle to build quickly. That does not mean any marketed product or biotech with an interesting pipeline is relevant. The case has to explain why ownership creates more value for Astellas than a licence, collaboration or supplier relationship.

It does not look like a broad company presentation followed by a request for Astellas to identify the useful asset. It does not look like a very early platform with no lead programme, no translational bridge and no credible CMC route. It does not look like an acquisition thesis built only on market size.

A serious package should already contain:

• a defined biological and strategic fit with an Astellas focus area or portfolio need
• comparative data showing why the asset or platform is differentiated
• a realistic development, regulatory and CMC path
• a clear IP position and an explicit description of available rights
• deal logic that matches the maturity and risk of the opportunity

Out-licensing and acquiring Astellas programmes

The opportunity can run in the opposite direction. A company may be able to acquire or license an Astellas programme that no longer fits the internal portfolio but remains scientifically valuable. The buyer must show that it has the capital, team, development plan and therapeutic commitment to move the programme. Interest without a credible ownership plan is unlikely to progress.

Japan’s recent portfolio reshaping is broader than Astellas. Our analysis of the Tanabe carve-out provides useful context: a programme or business can become more valuable under a different owner, but only when the strategic logic and execution capacity are real.

Open innovation

A real open-innovation proposal starts with one scientific question. It defines the experiment, the material or data needed, the success criteria, the ownership of results and the decision that follows. A short validation project that resolves an important uncertainty can be more attractive than an ambitious alliance without a first milestone.

It does not look like an invitation to explore synergies. It does not ask Astellas to educate the proposer, fund an unfocused research programme or accept unclear IP boundaries. Open innovation is a route into scientific work, not a substitute for a hypothesis.

Preclinical CRO

A real preclinical CRO opportunity connects a validated capability to a live development decision. Examples include a human-relevant model for retinal degeneration, translational toxicology for a new payload, an AAV biodistribution package, a biomarker that confirms target engagement, or a disease model that helps select between two candidates.

The same discipline appears in our analysis of Daiichi Sankyo’s ADC strategy. A model becomes commercially useful when it changes a target, payload, biomarker, safety or dose decision. A catalogue of assays does not create that connection. Your proposal should state what decision your work improves, what evidence supports the model and how quickly the answer can be delivered.

Clinical CRO

Astellas plans to internalise selected clinical operations, so a generic full-service pitch is weak. A stronger opportunity is a specialist capability that removes a defined bottleneck: rare-disease recruitment, ophthalmology site networks, oncology patient identification, complex sample logistics, decentralised elements, protocol simplification or high-quality execution in a difficult country or patient population.

Japan’s clinical-trial environment is changing, but regulatory flexibility does not recruit a single patient. A CRO proposal should include real site and patient feasibility, investigator access, start-up assumptions, recruitment evidence and a clear explanation of which responsibilities remain with Astellas.

CMC, CDMO and supply

A real manufacturing or supply opportunity removes a constraint that matters to an Astellas programme. That may be qualified AAV capacity, cell-therapy process control, ADC analytics, high-potency handling, comparability, fill and finish, device integration, cold-chain resilience or a credible second source for a critical material.

For cell and gene therapies, Japan’s regenerative medicine market adds regulatory, manufacturing and logistics requirements that must be addressed early. A supplier should show relevant quality history, technology-transfer discipline, capacity at the required scale, business-continuity planning and the ability to remain reliable when demand changes.

It does not look like: we can manufacture anything. Capacity without modality experience can add risk. Technical excellence without scale, transferability or continuity can become a future bottleneck.

Data, AI and digital tools

A real digital opportunity is embedded in a workflow and changes a measurable decision. It may improve target selection, protocol design, recruitment, monitoring, pathology interpretation, portfolio governance or manufacturing control. The proposal needs relevant data, validation, integration requirements, security and a clear human decision owner.

It does not look like an AI demonstration in search of a pharmaceutical problem. If the value depends on Astellas first building the data set, redesigning the workflow and discovering the use case, the proposition is not ready.

A useful test before contact

Before approaching Astellas, your team should be able to answer five questions:

• Which Astellas asset, strategic brand, Primary Focus or operating priority does this support?
• Which scientific, clinical, manufacturing or commercial decision will improve?
• What evidence proves performance in a comparable setting?
• Can your company protect IP, transfer the work and scale when the programme succeeds?
• What is the smallest useful next step that Astellas can approve?

If the first two answers are vague, you do not yet have an Astellas opportunity. You have a capability looking for one.

Where can service and supply companies fit?

Not every opportunity requires ownership of an asset.

There is one important qualification for clinical CROs. Astellas intends to internalise selected key clinical operations to increase control and consistency. A generic full-service outsourcing pitch may therefore be weak. Specialist capabilities that remove a bottleneck, improve patient access or accelerate execution remain much more credible.

For preclinical CROs, the same principle applies. Do not sell a catalogue. Connect a validated capability to a program decision, disease model, biomarker or modality-specific development problem.

For manufacturing and supply partners, Astellas is developing in-house capabilities while also partnering with external organisations. The opportunity is likely to be strongest in technically demanding areas such as AAV, cell therapy, ADCs, biologics, advanced analytics, device or delivery systems, cold chain and scale-up.

Suppliers should also expect serious scrutiny of quality, business continuity, human rights, environmental performance, data protection and occupational safety. Sustainable procurement is not decoration. It is part of supplier selection and monitoring.

Where are the opportunities in 2026, 2027 and 2028?

2026 to 2027: decisions, pivotal starts and enabling work

Astellas plans at least five Phase 3 or pivotal starts by FY2027, alongside proof-of-concept decisions across several pipeline assets.

This creates immediate openings in translational science, biomarker strategy, IND-enabling and pivotal-enabling work, trial preparation, specialised recruitment, clinical technology, CMC, manufacturing scale-up and external innovation.

For asset owners, this is also the window to present programs that are sufficiently de-risked to survive disciplined portfolio review.

2028: preparation for the FY2029 growth inflection

By 2028, attention should increasingly move from selection into execution. That is likely to increase demand for late-stage clinical support, global supply readiness, validation, technology transfer, launch manufacturing, market access evidence and lifecycle planning.

This is an inference from Astellas’ stated goal of pipeline-driven growth from FY2029. The exact need will depend on clinical results and portfolio decisions made during 2026 and 2027.

How should your company approach Astellas?

Start with the strategic fit, not your company history.

Your first approach should answer five questions:

1. Which Astellas goal or pipeline need do you support?
2. What evidence shows that your solution works?
3. Which timeline, risk or capability gap do you improve?
4. Why is your company difficult to replace?
5. What is the practical next step?

For an asset, prepare the biology, differentiation, intellectual-property position, development status, safety package, CMC readiness and realistic deal logic.

For a CRO or supply partner, show relevant case evidence, quality systems, capacity, continuity planning and the people who will actually deliver the work.

For an open-innovation proposal, define the experiment and decision point. Astellas needs to understand what becomes possible if the collaboration succeeds.

Japan rewards preparation. Astellas will reward relevance. The opportunity is not only to reach the right person, but to arrive with a proposal that fits the direction already approved inside the company.

We are your boots on the ground in supporting you in realising your opportunities

Between 2026 and 2028, Astellas must improve today’s commercial performance while building the pipeline that will matter from FY2029. That is a demanding transition, and it creates serious opportunities for assets, platforms, specialist CROs, manufacturing partners, suppliers and technology companies that solve a defined problem.

Reaching Astellas is not the same as creating commercial traction. As our Japan market-entry framework explains, meetings and polite interest are not the outcome. You need a proposition with strategic fit, evidence, a practical next step and an internal route to the people who own the problem.

Biosector can help you assess your Astellas fit before you spend months knocking on the wrong door. We can help sharpen your opportunity, stress-test your evidence, map the relevant functions and decision-makers, prepare your approach, open senior-level discussions and support the the process all the way to a deal in Japan.

We do not perform regulatory submissions or run clinical trials. Where specialist regulatory, clinical, CMC or other capabilities are required, we help you identify experienced partners.

Japan rewards preparation. Astellas will reward relevance, evidence and commitment. If your company has a distinctive asset, service, technology or supply capability and you are prepared to make a strategic investment to reach the market in Japan, book a meeting with Biosector or drop us an email at info@biosector.jp. Let us explore the fit together! It’s also important that our handshake is warm and mutual.

Astellas sources and publication note

This article is based on public Astellas information available on Sept 15, 2026, including CSP2021 and CSP2026, the Astellas partnering overview, Primary Focuses, open innovation, manufacturing and supply, the pipeline and sustainable procurement. Forward-looking statements and investigational programs may change.